Pulmonx

A would-be pulmonary pioneer enters the market via intubation.

The last 40 years have brought no major technological advances to intubation, the process of placing a tube in the trachea of a person with a medical need to secure an airway, says Peter Soltesz, a co-founder of Palo Alto, CA-based Pulmonxand its COO. Some 58 million intubations are performed annually worldwide, he says. Normally, the procedure is done quickly, without any complication. However, in many cases, the medical staffer performing an intubation cannot see what he or she is doing, and must proceed guided only by feel and sense of timing. The inability to visualize the anatomy can cause problems: tubes can, for instance, be misplaced in the esophagus or mainstem bronchus, which can lead to morbidity or death if undetected. Trouble happens, Soltesz says, in up to 10% of the emergency intubations performed outside of the hospital in the US each year. Even in calmer operating-room settings, where highly-experienced anesthesiologists typically perform the procedure, intubation can still cause problems 3-5% of the time—if, for instance, a patient turns out to have unusual anatomy. Intubation and tube positioning in infants and neonates are often difficult, simply because their airways are so small.

Pulmonx founders Rod Perkins, Peter Soltesz and Robert Kotmel figured the difficulties of intubation added up to a business opportunity,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Surgical Robotics CEOs Talk Metrics For Success, Valuations, Competition And IPO Outlook

 
• By 

Leaders of robotic systems companies Distalmotion, Neocis and Noah Medical discussed success metrics, competition and funding. Institutional investors are focusing on utilization, procedure rates and a clear path to profitability as the IPO window reopens, BTIG analyst Ryan Zimmerman said.

Dxcover Launches US Operations With New Headquarters In Tennessee

 

Dxcover sets up new Clinical Laboratory Improvement Amendments (CLIA) lab in Franklin, Tennessee.

Fallouh Healthcare Receives Grant Funding From Innovate UK

 

Fallouh Healthcare has received £305,050 in grant funding from Innovate UK as part of the European Union’s Eureka Eurostars program. The company aims to detect cardiac tamponade, a condition that affects patients after heart surgery. Currently, there is no way to accurately diagnose the condition.

FDA Regulations ‘Lock Out’ Clinically Proven Neuromodulation Devices

 

Flow Neuroscience's neuromodulation headset for the treatment of depression is approved and marketed in the EU. However, two years on, the company is still waiting for US FDA approval despite being assigned breakthrough device designation.

More from Business

Mexico’s New Procurement Rules Aim To Increase Healthcare Investment, But May Face Legal Trouble

 

Legal experts warn, however, that new Mexican procurement rules are discriminatory and could be challenged in the courts.

Will Kennedy And Makary Come To Terms On User Fees During Next Round Of MDUFA Negotiations?

 

It’s no secret that Marty Makary and Robert F. Kennedy Jr. have a different take on user fees, with Makary viewing them as a funding necessity and Kennedy as a corrupting influence. But will they find a way to strike a balance during the next MDUFA reauthorization talks so each can claim victory?

FDA Regulations ‘Lock Out’ Clinically Proven Neuromodulation Devices

 

Flow Neuroscience's neuromodulation headset for the treatment of depression is approved and marketed in the EU. However, two years on, the company is still waiting for US FDA approval despite being assigned breakthrough device designation.